Zemaira is used for chronic augmentation and maintenance therapy for adults with Alpha-1 deficiency and emphysema. Zemaira® has been shown to be safe and effective, with half or less the infusion volume and time of other Alpha-1 therapies.*,1-3

What should you expect from Zemaira®?

Effective Therapy

  • Zemaira® effectively raises Alpha-1 levels

High Purity
  • Zemaira® is the only Alpha-1 augmentation therapy approved by the FDA as highly purified
  • At least 94% of proteins are Alpha-1 (at least 60% for Prolastin®)**,1,2
  • Delivers very few nontherapeutic proteins per dose

Convenience
  • Half the infusion volume or less2,3
  • Half the infusion time or less*,1-3
  • Room temperature storage and transport
  • Easy reconstitution

Well-Tolerated Therapy
  • Generally well tolerated
  • No evidence of viral transmission in clinical studies

Patient Support
  • Alpha-1 Guardian Program—A personal health management program that offers support, guidance and education for patients with Alpha-1
  • CSL Behring® AssuranceSM for Zemaira®—Eligible patients who rely on Zemaira® can continue receiving treatment even if they experience a lapse in their third-party, private health insurance

 Prolastin® is a registered trademark of Talecris Corporation.

 
*Based on recommended dosage as stated in the product package inserts of 60 mg/kg body weight at the infusion rate of 0.08 mL/kg/min.

 
**Manufacturer's release specification. Shelf-life specification is ≥ 90%.
Important Safety Information

Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema.

Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available.

As with other Alpha-1 therapies, Zemaira® may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For more information about Zemaira®, please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  1. Data on file, CSL Behring LLC.
  2. Prolastin® Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, March 2003.
  3. Aralast™ Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, January 2003.
About Zemaira®